Table 3. Comparison of PSA decline and FCH PET/CT in non-progressing vs progressing patients.
| Response at Follow-up FCH PET/CT Imaging Studya | PSA Response | Total | |
|---|---|---|---|
| PSA <50% | PSA >50% | ||
| NonProgression | 18b (75%) | 6c (25%) | 24 (57%) |
| Progression | 2d (11%) | 16 (89%) | 18 (43%) |
| Total | 20 (48%) | 22 (52%) | 42 (100%) |
a
Nonprogression was defined as complete response, partial remission or stable disease; progression was defined as progressive disease.
b
Including 3 patients with bone flare at FCH PET/CT, and 1 patient with partial remission at PET but liver progression at 3-month CT only.
c
Including 1 patient with bone flare at at FCH PET/CT with PSA decline = 37.2% after 6 months of available follow-up, and one patient with PSA decline = 48.8%.
d
1 patient suspected for bone flare, but PET scan was not repeated due to severe intestinal infection with treatment interruption and clinical deterioration.